Compare Novo Nordisk A/S (NVO) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Realty Income Corp — how do they compare? Novo Nordisk A/S trades at $38.15 (market cap $165.31B), while Realty Income Corp trades at $54.27 (market cap $51.26B). The key difference: Novo Nordisk A/S is far larger — about 3.2× Realty Income Corp's market cap, and Realty Income Corp pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Realty Income Corp for 127 Days on average.
| NVO | O | |
|---|---|---|
Market Cap | $165.31B | $51.26B |
Volume | 11,432,838 | 12,300,266 |
Sector | Health | Real Estate |
52-Week High | $63.98 | $67.56 |
52-Week Low | $35.29 | $53.35 |
Typical Hold Time | 116 Days | 127 Days |
Enterprise Value | $179.56B | $81.88B |
Dividend Yield | 4.71% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Realty Income (O) trades at $53.35, down 1.66% amid bearish technical signals and recent earnings misses. The REIT maintains strong fundamentals with 92.56% gross margins and consistent dividend payments, though rising bond yields pressure valuations. Analyst consensus remains cautiously optimistic with a $64.80 price target despite three consecutive quarterly EPS misses.
The stock faces near-term headwinds from technical weakness and interest rate sensitivity, but long-term investors may find value in the 6%+ dividend yield and A-rated balance sheet. Key risks include persistent earnings underperformance and debt levels approaching 40% of assets, requiring careful monitoring of Q3 2026 results due November 2.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
